Bristol-Myers Squibb Co., has added warnings to the label for the antibiotic Tequin. The antibiotic is used to treat various infections, including pneumonia, bronchitis and kidney infections. Since the approval of Tequin in 1999, there have been cases of life-threatening events. The new labeling contains updated warnings reflecting information from continued reports of serious hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar). Also, the revised Tequin prescribing information includes a contraindication in diabetic patients due to the serious reports of hypoglycemia and hyperglycemia. Sheller, Ludwig and Badey is investigating claims of injury caused by Tequin.
Comments are closed.